Bone Histomorphometry and Bone Quality
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Black D, Greenspan S, Ensrud K, Palermo L, McGowan J, Lang T
. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med. 2003; 349(13):1207-15.
DOI: 10.1056/NEJMoa031975.
View
2.
Chavassieux P, Karsdal M, Segovia-Silvestre T, Neutzsky-Wulff A, Chapurlat R, Boivin G
. Mechanisms of the anabolic effects of teriparatide on bone: insight from the treatment of a patient with pycnodysostosis. J Bone Miner Res. 2008; 23(7):1076-83.
DOI: 10.1359/jbmr.080231.
View
3.
Chavassieux P, Seeman E, Delmas P
. Insights into material and structural basis of bone fragility from diseases associated with fractures: how determinants of the biomechanical properties of bone are compromised by disease. Endocr Rev. 2007; 28(2):151-64.
DOI: 10.1210/er.2006-0029.
View
4.
Seeman E, Delmas P
. Bone quality--the material and structural basis of bone strength and fragility. N Engl J Med. 2006; 354(21):2250-61.
DOI: 10.1056/NEJMra053077.
View
5.
Delmas P, Vergnaud P, Arlot M, Pastoureau P, Meunier P, Nilssen M
. The anabolic effect of human PTH (1-34) on bone formation is blunted when bone resorption is inhibited by the bisphosphonate tiludronate--is activated resorption a prerequisite for the in vivo effect of PTH on formation in a remodeling system?. Bone. 1995; 16(6):603-10.
DOI: 10.1016/8756-3282(95)00113-r.
View